RBC Life Science and Technology Fund

Fund Category
Science & Technology Equity

Morningstar Rating™
★★★

Investment Objective

To provide long-term capital growth by investing primarily in equity securities of U.S. companies whose businesses relate to life sciences and technology and are expected to benefit from scientific and technological advances.

Fund Details

Series	Load Structure	Currency	Fund Code
A	No Load	CAD	RBF274
F	No Load	CAD	RBF619

Inception Date	July 1995
Total Assets $Mil	92.0
Series A NAV $	4.97
Series A MER %	2.11
Benchmark	50% S&P 500 Health Care 50% S&P 500 Info Tech (measured in $C)
Income Distribution	Annually
Capital Gains Distribution	Annually
Sales Status	Open
Min. Investment $	500
Subsequent Investment $	25
RRSP Eligibility	Yes
Management Company	RBC Asset Management Inc.
Web Site	www.rbcam.com

Portfolio Analysis as of September 30, 2009

Asset Mix



	% Assets
Cash	3.4
Fixed Income	0.0
Canadian Equity	1.4
US Equity	89.5
International Equity	5.8
Other	0.0

Equity Style



Equity Statistics

P/B Ratio	2.3
P/E Ratio	23.9
Avg Mkt Cap $Bil	7.7

Top 5 Sectors	% Equity
Information Technology	85.2
Health Care	14.3
Industrials	0.5
Consumer Discretionary	0.0
Consumer Staples	0.0

Top Geographic Allocations	% Assets
United States	89.5
Canada	4.7
Singapore	1.4
Netherlands	1.2
Israel	1.0

Top 25 Holdings	% Assets
Apple, Inc.	3.4
Cash & Cash Equivalent	3.4
Cisco Systems, Inc.	2.3
EMC Corporation	2.2
Google, Inc.	2.1
Microsoft Corporation	2.1
Hewlett-Packard Company	2.0
Broadcom Corporation	1.8
Intel Corporation	1.7
Micron Technology, Inc.	1.7
International Business Machines Corp	1.6
KLA-Tencor Corporation	1.5
Motorola, Inc.	1.4
Flextronics International, Ltd.	1.4
Teradyne, Inc.	1.3
Ciena Corporation	1.3
Advanced Micro Devices	1.3
Marvell Technology Group, Ltd.	1.3
Cymer, Inc.	1.3
Amkor Technology, Inc.	1.3
Dell, Inc.	1.3
NetLogic Microsystems, Inc.	1.3
Juniper Networks, Inc.	1.2
Analog Devices, Inc.	1.2
ON Semiconductor Corporation	1.2
Total % of Top 25 Holdings	42.6
Total Number of Stock Holdings	90
Total Number of Bond Holdings	0
Total Number of Other Holdings	1
Total Number of Holdings	**91**

Performance Analysis as of September 30, 2009



	2000	2001	2002	2003	2004	2005	2006	2007	2008	YTD	
	-0.6	-31.4	-48.0	16.6	-9.2	-3.0	-1.8	0.5	-29.3	18.8	Fund
	1st	2nd	3rd	4th	4th	3rd	4th	2nd	2nd	4th	Quartile

1 Mth	3 Mth	6 Mth	1 Yr	3 Yr	5 Yr	10 Yr	Since Incep.	**Trailing Return %**
3.2	6.6	16.9	2.8	-3.8	-2.9	-8.1	-0.3	Fund
3rd	3rd	3rd	4th	4th	4th	2nd	—	Quartile

RBC Life Science and Technology Fund

Management Overview

Manager Bios

Ray Mawhinney
RBC Asset Management Inc.
Ray Mawhinney is Senior Vice President and Portfolio Manager, U.S. and Global Equities, RBC Asset Management Inc. Industry experience since 1984.

Cameron Scrivens, M.B.A.
RBC Asset Management Inc.
Cameron Scrivens is Vice President and Senior Portfolio Manager, U.S. and Global Equities. He has been in the Investment Industry since 1992.

Performance Analysis Cont'd as of September 30, 2009

Distributions ($)/Unit	YTD	2008	2007	2006	2005	2004	2003	2002	2001	2000
Total Distributions	—	—	—	—	—	—	—	—	—	7.50
Interest	—	—	—	—	—	—	—	—	—	—
Dividends	—	—	—	—	—	—	—	—	—	—
Capital Gains	—	—	—	—	—	—	—	—	—	7.50
Return Of Capital	—	—	—	—	—	—	—	—	—	—

Best/Worst Periods %		1Yr		3Yr		5Yr		10Yr
Best	2-2000	138.3	2-2000	48.4	8-2000	34.7	7-2005	1.7
Worst	9-2001	-61.9	2-2003	-37.9	8-2005	-23.8	1-2009	-9.4
Average		3.0		2.9		-0.6		-2.9
No. of Periods		159		135		111		51
Pct. Positive		51.6		38.5		24.3		17.6

Quarterly Commentary as at September 30, 2009

The RBC Life Science and Technology Fund (Series A) gained 6.6% in the third quarter, compared to 5.5% return for its benchmark.

Strong corporate earnings were a major catalyst for equity moves in the quarter as the majority of global companies either met or beat expectations.

Specifically related to global technology, demand has returned to computing, and to a lesser extent, handsets, but the biggest influence of demand came from restocking depleted inventory levels. Looking forward, areas that have not seen dramatic improvement such as telecom and enterprise software will be next for recovery. Geographically, emerging markets have witnessed the fastest rebound while Europe and North America are slowly recovering. In this environment, companies with strong distribution, market share and new product cycles tend to fare best and this is where the Fund is positioned.

Performance of defensive, non-cyclical sectors like Health Care again lagged behind cyclical sectors, while uncertainties from U.S. health care reform further added to headwinds facing Health Care. European health care companies made a strong come back, benefiting from the temporary overhang in U.S. pharmaceuticals, as investors awaited approval of the megamergers and from the more consumer discretionary nature of European health care equipment and supply companies.

Within the Fund, companies such as Flextronics, Micron technology, Salesforce.com, SXC Health Solutions and Intuitive Surgical Inc. helped Fund performance. Meanwhile, investments in Oracle, Qualcomm, UnitedHealth Group and Merck & Co., detracted.

We remain optimistic that the bottom in the equity markets has been seen and global economic recovery is underway. Market pull backs are always possible, especially given the speed and magnitude of the current recovery, but we feel any correction should be well contained.

Major Buys
Motorola
3com Corp
WuXi PharmaTech
Express Scripts Inc.

Major Sells
Texas Instruments
BigBand networks
Crucell NV ADR
Quest Diagnostics

RBC Life Science and Technology Fund

Disclosure

RBC Funds are offered by RBC Asset Management Inc. and distributed through authorized dealers.

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus of the mutual fund before investing. Except as otherwise noted, the indicated rates of return are the historical annual compounded total returns including changes in unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any unitholder that would have reduced returns. Mutual funds are not guaranteed or covered by the Canadian Deposit Insurance Corporation or by any other government deposit insurer. The value of mutual funds change frequently and past performance may not be repeated.

The Top 25 Holdings may change due to ongoing portfolio transactions within the fund. The Prospectus and other information about the underlying investment funds are available at www.sedar.com.

Graphs are only used to illustrate the effects of the compound growth rate and do not reflect future values of any fund or returns on investment of any fund.

This fund profile is provided for informational purposes only. Particular investments and/or trading strategies should be evaluated relative to each individual's investment objectives. The information contained in this fund profile is not, and should not be construed as, investment or tax advice. You should not act or rely on the information contained in this fund profile without seeking the advice of an appropriate professional advisor.

For money market funds, the performance data assumes reinvestment of distributions only and does not take into account sales, redemption, distribution or optional charges or income taxes payable by any unitholder that would have reduced returns. In addition, for money market funds, there can be no assurances that the fund will be able to maintain its net asset value per unit at a constant amount or that the full amount of your investment in the fund will be returned to you.

Quartile rankings are determined by Morningstar Research Inc., an independent research firm. Quartile rankings are comparisons of the performance of a fund to other funds in a particular category and are subject to change monthly. The quartiles divide the data into four equal segments expressed in terms of rank (1, 2, 3 or 4). This is the Morningstar quartile ranking of Series A units of the Fund as of September 30, 2009.

Morningstar ratings are overall ratings reflecting risk adjusted performance as of September 30, 2009. The ratings are subject to change every month. The ratings are calculated for funds with a minimum of 3 years of performance, calculated from the funds' 1 and 3 year average annual returns measured against a 91-day Treasury Bill return with appropriate fee adjustments. The top 10% of the funds in a category receive 5 stars (high); if the funds fall in the next 22.5%,they receive 4 stars (above average); a place in the middle 35% earns a fund 3 stars (neutral or average); those in the next 22.5% receive 2 stars (below average); and the lowest 10% get 1 star (low). Ratings are just one factor to consider when investing. For more information, please see www. morningstar.ca.